PharmaLive and Med Ad News editors present the prescription medicines in development for the world's top 50 biotechnology companies. The top companies are determined based on their health-care revenue generated during 2006.
The pipelines are presented by company in alphabetical order. The lists in this special report provide the following for each product: chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer.
These phases of the pipeline have been considered for this special report - preclinical development, Phase I, Phase II, Phase III and awaiting approval. This report concentrates on prescription products in development in the United States, Europe and Japan. Additionally included in this report is a chart containing the 2006 health-care revenue and 2006, 2005 and 2004 R&D expenditure for the top 50 companies.